|1.||Liao, Er-yuan: 3 articles (12/2004 - 02/2003)|
|2.||Zhou, Hou-de: 2 articles (12/2004 - 02/2003)|
|3.||Liao, Hui-juan: 2 articles (05/2003 - 02/2003)|
|4.||Wu, Xian-ping: 2 articles (05/2003 - 02/2003)|
|5.||Luo, Xiang-hang: 2 articles (05/2003 - 02/2003)|
|6.||Zhou, Houde: 1 article (12/2010)|
|7.||Liao, Eryuan: 1 article (12/2010)|
|8.||Yang, Kaichu: 1 article (12/2010)|
|9.||Xu, L-L: 1 article (04/2009)|
|10.||Ma, M-H: 1 article (04/2009)|
09/01/1993 - "In conclusion, nylestriol is a convenient and acceptable drug which was beneficial for relieving climacteric syndrome, preventing osteoporosis and improving lipoprotein lipid pattern."
02/01/2003 - "To determine an optimal dosage combination for a nylestriol/levonorgestrel (NYL/LNG) regimen in the treatment of female Sprague-Dawley (SD) rats with retinoic acid (RA)-induced osteoporosis in order to examine the rationale of NYL/LNG use for postmenopausal women. "
02/01/2003 - "Effects of different nylestriol/levonorgestrel dosages on bone metabolism in female Sprague-Dawley rats with retinoic acid-induced osteoporosis."
|2.||Osteosarcoma (Osteogenic Sarcoma)
|3.||Body Weight (Weight, Body)
04/01/2009 - "The OVX rats were then subdivided into five groups treated with water, nylestriol (1 mg/kg body weight, weekly, orally) or icariin (ICA) (5, 25, and 125 mg/kg body weight, daily, orally) for 12 weeks. "
08/01/2004 - "Three dosage levels of CNT (0.039, 0.117 and 0.39 mg/kg body weight, daily), nylestriol (NYL, 0.30, 0.09 and 0.03 mg/kg body weight, daily) and levonorgestrel (LEV, 0.09, 0.027 and 0.009 mg/kg body weight, daily) were designed to prevent the bone loss of the osteoporotic rat model induced by RA and OVX respectively. "
05/01/2003 - "In addition to the animal experiments, we evaluate the effect of Compound Nylestriol Tablet (CNT) on bone mineral density (BMD) in women with postmenopausal osteoporosis. "
05/01/2003 - "The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis."
05/01/2003 - "Compound Nylestriol Tablet, which contains 0.5 mg of nylestriol (cyclopentylethinyl estriol) and 0.15 mg of levonorgestrel per tablet, was authorized as a new anti-osteoporotic agent for clinical trial in postmenopausal osteoporosis. "
|5.||Atrophic Rhinitis (Ozena)
|2.||Levonorgestrel (Plan B)
|3.||Interleukin-6 (Interleukin 6)
|4.||Tretinoin (Retinoic Acid)